GlassScriptPhysician profile
Joseph J La Conti
NPI 1831465954
$345,423.70
in general payments reported to CMS, 2019-2025
46 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $18K · 2021: $23K · 2022: $42K · 2023: $65K · 2024: $73K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $205K · Travel and Lodging: $26K · Food and Beverage: $15K · Consulting Fee: $3,660 · Education: $16.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $205,375.00 |
| Travel and Lodging | $26,343.93 |
| Food and Beverage | $15,064.86 |
| Consulting Fee | $3,660.00 |
| Education | $16.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241,934.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $84,694.38 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $5,887.89 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $2,173.17 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Mallinckrodt Hospital Products INC. | $2,099.68 | 2021-2025 | Acthar |
| Ucb, INC. | $1,436.04 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,355.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.06 | 2022-2025 | Cyltezo, Ofev |
| Aurinia Pharma U.S., INC. | $650.52 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $581.34 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $553.37 | 2019-2025 | |
| Lilly USA, LLC | $456.09 | 2020-2024 | Taltz |
| Pfizer INC. | $288.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $258.72 | 2019-2025 | Orencia |
| Depuy Synthes Sales INC. | $256.48 | 2022-2025 | Orthovisc, Monovisc, Peak |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph La Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.